| Molecular Weight: | 376.41 |
| Formula: | C21H20N4O3 |
| Purity: | ≥98% |
| CAS#: | 209783-80-2 |
| Solubility: | DMSO up to 100 mM |
| Chemical Name: | pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate |
| Storage: | Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year. |
Biological Activity:
Entinostat (MS-275) is a potent and selective HDAC inhibitor. It inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, but not the other HDACs 4, 6, 8, and 10 (IC50 > 100 µM). MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. It was shown to reduce S-phase cells and induce G1-phase cells in A2780 cells. MS-275 shows great inhibition to human leukemia and lymphoma cells, decreases expression of cyclin D1 and the anti-apoptotic proteins Mcl-1 and XIAP. In vivo MS-275 exhibits great antitumor activity against human tumor xenografts. Currently it is in Phase II/III clinical trials for Hodgkin's lymphoma and advanced breast cancer.
How to Use:
- In vitro: Entinostat (MS-275) was used at 1 µM final concentration in vitro and in cellular assays.
- In vivo: Entinostat (MS-275) was orally dosed to mice at 49 mg/kg once daily 5 days per week for 4 weeks in the xenograft tumor model.
Reference:
- 1. Saito A, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. (1999) Proc Natl Acad Sci USA. 96(8):4592-7.
- 2. Rosato RR, et al.The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. (2003) Cancer Res. 63(13):3637-45.
- 3. Kato Y, et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. (2007) Clin Cancer Res. 13(15 Pt 1):4538-46.
Products are for research use only. Not for human use.
